Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Savolitinib - AstraZeneca/HUTCHMED

Next Previous
Drug Profile

Savolitinib - AstraZeneca/HUTCHMED

Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; Voressa

Latest Information Update: 05 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Preregistration Gastric cancer
  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Oesophageal cancer; Prostate cancer
  • No development reported CNS cancer; Solid tumours

Most Recent Events

  • 30 Dec 2025 Preregistration for Gastric cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (PO)
  • 30 Dec 2025 China NMPA accepts NDA for Savolitinib for Gastric cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) for review
  • 30 Dec 2025 Savolitinib receives priority review status for Gastric cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top